US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,592.00

-7.0786-0.27%

Number of Gainers:2

Number of Losers:3

Number of Flat:- -

PE:- -

High:2,661.42

Open:2,596.90

Low:2,514.05

Close:2,599.07

Volume:11.36M

Turnover:295.33M

Market Cap:41.66B

Float Cap:40.81B

Loading ...

Teva Pharmaceutical Says FDA Accepts New Drug Application for Olanzapine in Schizophrenia Treatment

MT Newswires Live

FDA accepts Teva NDA for olanzapine extended-release injectable suspension

BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents

Corcept Therapeutics Inc - Ruling Affirms December 2023 Verdict by Federal District Court

THOMSON REUTERS

Corcept Therapeutics Inc - Considering Judicial Review of Court Decision

THOMSON REUTERS

Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals

THOMSON REUTERS

MannKind CEO Michael Castagna to Present at Oppenheimer Healthcare Life Sciences Conference

Veru CEO Mitchell Steiner to Present at Oppenheimer Healthcare Life Sciences Conference

MannKind Corporation Schedules Webcast to Review Financial Results and Business Update

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Femasys Inc. Files Initial Beneficial Ownership Statement for CTO Jeremy Alexander Sipos

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Benzinga_recent_news

Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s

BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease

Teva: Duvakitug Was Well Tolerated and Safety Was Consistent With Induction Study

THOMSON REUTERS

Teva and Sanofi’s Duvakitug Phase 2B Maintenance Data Demonstrated Clinically Meaningful Durable Efficacy in Ulcerative Colitis and Crohn’s Disease

THOMSON REUTERS

Analysts Are Bullish on These Healthcare Stocks: CAMP4 Therapeutics Corporation (CAMP), Veru (VERU)

MannKind’s Pediatric Afrezza Trial Puts Needle Free Insulin Thesis To Test

Simply Wall St.

Femasys Secures Regulatory Approvals for FemBloc and Other Products in Multiple Regions

Veru Inc. Charts Risky but Clearer Post-GLP-1 Path

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2591.9956,"timestamp":1771621199999,"preClose":2599.0742,"halted":0,"volume":11362854,"delay":0,"changeRate":-0.002724,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-7.078613,"latestTime":"02-20 16:00:00 EST","open":2596.8997,"high":2661.4155,"low":2514.0496,"amount":295334513.65556,"amplitude":0.056699,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.281475,"peRate":30.210268,"turnoverRate":0.007515,"increases":2,"decrements":3,"flats":0,"marketCap":41662837666,"floatMarketCap":40810627756},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2661.4155,"amplitude":0.056699,"preClose":2599.0742,"low":2514.0496,"pbRate":"5.281475","latestPrice":2591.9956,"volume":11362854,"delay":0,"open":2596.8997,"prevYearClose":2379.9924,"prevWeekClose":2576.6284,"prevMonthClose":2591.3975,"prevQuarterClose":2379.9924,"fiveDayClose":2571.6028,"twentyDayClose":2418.0854,"sixtyDayClose":1862.2355,"secType":"PLATE","market":"US","turnoverRate":0.007515,"peRate":30.210268,"marketCap":41662837666,"floatMarketCap":40810627756,"timestamp":1771621199999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":2,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613829408","title":"Teva Pharmaceutical Says FDA Accepts New Drug Application for Olanzapine in Schizophrenia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2613829408","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613829408?lang=en_us&edition=fundamental","pubTime":"2026-02-21 04:05","pubTimestamp":1771617940,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  said Friday that the US Food and Drug Administration has accepted the company's New Drug Application for olanzapine extended-release injectable suspension, or TEV-'749, for the treatment of schizophrenia in adults.The application for TEV-'749 is based on results from the phase 3 Solaris trial that demonstrated an efficacy and safety profile consistent with other available olanzapine formulations, and showed no evidence for the need for post-injection monitoring, Teva Pharmaceutical Industries said.Shares of the company were down over 1% in recent Friday trading.Price: 34.00, Change: -0.33, Percent Change: -0.96","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TEVA","LU1983299246.USD","BK4584","BK4588","BK4596","BK4559","LU2324357040.USD","BK4566","BK4557","BK4007","BK4585"],"gpt_icon":0},{"id":"2613129475","title":"FDA accepts Teva NDA for olanzapine extended-release injectable suspension","url":"https://stock-news.laohu8.com/highlight/detail?id=2613129475","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613129475?lang=en_us&edition=fundamental","pubTime":"2026-02-21 03:55","pubTimestamp":1771617319,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Medincell announced that the U.S. Food and Drug Administr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-accepts-teva-nda-for-olanzapine-extended-release-injectable-suspension-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-accepts-teva-nda-for-olanzapine-extended-release-injectable-suspension-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","TEVA","LU1983299246.USD","LU2324357040.USD","BK4557","BK4559","BK4584","BK4007","BK4596","BK4566"],"gpt_icon":0},{"id":"2612929235","title":"BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2612929235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612929235?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:35","pubTimestamp":1771536943,"startTime":"0","endTime":"0","summary":"BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept PatentsFeb 19 (Reuters) - Corcept Therapeutics Inc CORT.O:CORCEPT PROVIDES UPDATE ON PATENT DISPUTE WITH TEVA PHARMACE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU2324357040.USD","BK4585","TEVA","BK4584","BK4566","BK4596","LU1559883803.SGD","BK4007","BK4588","BK4532","BK4557","CORT","LU0566484027.USD","BK4559"],"gpt_icon":0},{"id":"2612728001","title":"Corcept Therapeutics Inc - Ruling Affirms December 2023 Verdict by Federal District Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2612728001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612728001?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:00","pubTimestamp":1771534800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4566","LU2324357040.USD","LU1559883803.SGD","BK4596","LU1983299246.USD","BK4559","BK4584","BK4585","BK4588","CORT","TEVA","BK4532","LU0566484027.USD","BK4557","BK4007"],"gpt_icon":0},{"id":"2612280046","title":"Corcept Therapeutics Inc - Considering Judicial Review of Court Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2612280046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612280046?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:00","pubTimestamp":1771534800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","BK4588","BK4532","BK4584","BK4557","LU0566484027.USD","LU2324357040.USD","CORT","LU1983299246.USD","BK4559","TEVA","BK4596","BK4585","BK4566","BK4007"],"gpt_icon":0},{"id":"2612044280","title":"Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2612044280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612044280?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:00","pubTimestamp":1771534800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CORT","LU2324357040.USD","LU1559883803.SGD","BK4532","LU1983299246.USD","BK4585","BK4584","LU0566484027.USD","BK4559","BK4588","TEVA","BK4566","BK4596","BK4557","BK4007"],"gpt_icon":0},{"id":"2612288748","title":"MannKind CEO Michael Castagna to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612288748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612288748?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:02","pubTimestamp":1771509725,"startTime":"0","endTime":"0","summary":"MannKind CEO Michael Castagna to Present at Oppenheimer Healthcare Life Sciences Conference               MannKind Corporation (Nasdaq: MNKD) said CEO Michael Castagna will present and provide busines","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL8LLrCh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","LU2095319765.USD","BK4584","LU0314104364.USD","LU2210150020.SGD","SG9999014039.USD","BK4112","SG9999014021.USD","SG9999014013.SGD","SG9999014005.SGD","IE00BKPKM429.USD","NDAQ","MNKD","LU2210149790.SGD","BK4588","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2612729400","title":"Veru CEO Mitchell Steiner to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612729400","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612729400?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:32","pubTimestamp":1771507976,"startTime":"0","endTime":"0","summary":"Veru CEO Mitchell Steiner to Present at Oppenheimer Healthcare Life Sciences Conference               Veru Inc. (NASDAQ: VERU) said its Chairman, President and CEO Mitchell Steiner, M.D., will present","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL601bSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","SG9999014039.USD","LU2210150020.SGD","BK4588","BK4584","LU2210149790.SGD","SG9999014021.USD","BK4007","BK4112","BK4183","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","VERU","IE00BKPKM429.USD","BK4557","SG9999014005.SGD"],"gpt_icon":0},{"id":"2612544961","title":"MannKind Corporation Schedules Webcast to Review Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2612544961","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612544961?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:00","pubTimestamp":1771423256,"startTime":"0","endTime":"0","summary":"MannKind Corporation Schedules Webcast to Review Financial Results and Business Update               MannKind Corporation said it will release its fourth quarter and full year 2025 financial results b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL1t6dlP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2095319765.USD","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4588","IE00BKPKM429.USD","SG9999014013.SGD","BK4139","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014005.SGD","BK4585","IE00BGHQF748.EUR","NDAQ","LU0314104364.USD","MNKD","BK4584"],"gpt_icon":0},{"id":"2612415894","title":"MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612415894","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612415894?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:00","pubTimestamp":1771423200,"startTime":"0","endTime":"0","summary":"Investor Relations. Kate Miranda. (617) 921-5461. Email: ir@mnkd.com. Media Relations. Christie Iacangelo. (818) 292-3500. Email: media@mnkd.com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240267/29517/en/MannKind-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-26-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MNKD","BK4139"],"gpt_icon":0},{"id":"2612947496","title":"Femasys Inc. Files Initial Beneficial Ownership Statement for CTO Jeremy Alexander Sipos","url":"https://stock-news.laohu8.com/highlight/detail?id=2612947496","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612947496?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:46","pubTimestamp":1771368367,"startTime":"0","endTime":"0","summary":"Femasys Inc. has filed an initial statement of beneficial ownership. The filing lists Jeremy Alexander Sipos, Chief Technology Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL5lTjFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Femasys Inc. Files Initial Beneficial Ownership Statement for CTO Jeremy Alexander Sipos","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","FEMY","BK4539","BK4584"],"gpt_icon":0},{"id":"2612745489","title":"Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2612745489","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612745489?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:04","pubTimestamp":1771329840,"startTime":"0","endTime":"0","summary":"Teva stock rises after a new study, in partnership with Sanofi, shows lasting benefits in ulcerative colitis and Crohn's patients.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/17/Teva-Pharmaceuticals.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/17/Teva-Pharmaceuticals.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/26/02/50645029/teva-pharmaceuticals-new-study-shows-lasting-relief-for-inflammatory-bowel-disease-patients","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/26/02/50645029/teva-pharmaceuticals-new-study-shows-lasting-relief-for-inflammatory-bowel-disease-patients","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SNY","BK4559","BK4588","BK4584","BK4596","BK4007","BK4217","BK4585","LU2324357040.USD","BK4566","LU1983299246.USD","TEVA","IE00BFXG1179.USD","BK4557","SMA"],"gpt_icon":0},{"id":"2612456221","title":"Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s","url":"https://stock-news.laohu8.com/highlight/detail?id=2612456221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612456221?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:16","pubTimestamp":1771326961,"startTime":"0","endTime":"0","summary":"Teva (TEVA) and Sanofi (SNY) announced positive results from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human mono...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-and-sanofis-duvakitug-phase-2b-data-shows-efficacy-in-colitis-and-crohns-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-and-sanofis-duvakitug-phase-2b-data-shows-efficacy-in-colitis-and-crohns-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SNYNF","LU2324357040.USD","BK4596","BK4584","BK4557","LU1983299246.USD","SNY","BK4588","TEVA","BK4566","BK4585","IE00BFXG1179.USD","BK4559"],"gpt_icon":0},{"id":"2612456940","title":"BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2612456940","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612456940?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:09","pubTimestamp":1771326599,"startTime":"0","endTime":"0","summary":"BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's DiseaseFeb 17 (Reuters) - Sanofi SA SASY.PA:SANOFI AND TEVA’S DUVAKITUG PHASE 2B MAINTENANCE DATA DEMONSTRAT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUAM4KSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LU1983299246.USD","TEVA","BK4584","LU2324357040.USD","BK4557","BK4559","BK4566","BK4007","BK4596"],"gpt_icon":0},{"id":"2612563414","title":"Teva: Duvakitug Was Well Tolerated and Safety Was Consistent With Induction Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2612563414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612563414?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:00","pubTimestamp":1771326001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA8BNFHC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4566","TEVA","BK4557","LU1983299246.USD","BK4585","BK4559","BK4596","LU2324357040.USD","BK4588","BK4007"],"gpt_icon":0},{"id":"2612456842","title":"Teva and Sanofi’s Duvakitug Phase 2B Maintenance Data Demonstrated Clinically Meaningful Durable Efficacy in Ulcerative Colitis and Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2612456842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612456842?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:00","pubTimestamp":1771326001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA8BNFHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","LU1983299246.USD","BK4585","BK4584","TEVA","BK4559","BK4588","BK4566","BK4596","BK4557","BK4007"],"gpt_icon":0},{"id":"2611710522","title":"Analysts Are Bullish on These Healthcare Stocks: CAMP4 Therapeutics Corporation (CAMP), Veru (VERU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611710522","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611710522?lang=en_us&edition=fundamental","pubTime":"2026-02-16 13:41","pubTimestamp":1771220466,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CAMP4 Therapeutics Corporation (CAMP – Research Repo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-camp4-therapeutics-corporation-camp-veru-veru-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-camp4-therapeutics-corporation-camp-veru-veru-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","BK4557","BK4112","BK4007","XBI","BK4137","LU0029874061.USD","BK4581","VERU","BK4588","BLSG","BK4139","BK4020","LABU","BK4585","BLSX","CAMP","LU0128526141.USD","BK4584"],"gpt_icon":0},{"id":"2611175495","title":"MannKind’s Pediatric Afrezza Trial Puts Needle Free Insulin Thesis To Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2611175495","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611175495?lang=en_us&edition=fundamental","pubTime":"2026-02-16 04:22","pubTimestamp":1771186925,"startTime":"0","endTime":"0","summary":"MannKind (NasdaqGM:MNKD) has started enrolling pediatric patients in its pivotal INHALE-1ST trial of Afrezza inhaled insulin.\nThe study focuses on using Afrezza shortly after a type 1 diabetes diagnosis in children and adolescents.\nThe FDA is currently reviewing a supplemental application to expand Afrezza’s label to pediatric use, with a decision expected in the coming months.\nIf cleared, Afrezza could become the first needle free insulin option for young patients in the US.\n\nShares of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkinds-pediatric-afrezza-trial-puts-needle-free-insulin-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkinds-pediatric-afrezza-trial-puts-needle-free-insulin-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MNKD","BK4584","BK4139"],"gpt_icon":0},{"id":"2611947161","title":"Femasys Secures Regulatory Approvals for FemBloc and Other Products in Multiple Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2611947161","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611947161?lang=en_us&edition=fundamental","pubTime":"2026-02-14 00:56","pubTimestamp":1771001802,"startTime":"0","endTime":"0","summary":"Femasys Inc. has received key regulatory approvals for several of its products. The company obtained approval for its FemBloc non-surgical permanent birth control to enable commercialization in Europe, the United Kingdom, and New Zealand. Additionally, FemaSeed, FemVue, and FemCerv received approval for commercialization in the United Kingdom, Israel, and Australia. Femasys also secured FDA Investigational Device Exemption  approval to advance the FemBloc FINALE pivotal clinical trial to its final phase, which is required for U.S. regulatory approval. These milestones support Femasys' efforts to expand its portfolio in women's reproductive health.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original conten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL5y7KjG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","FEMY","BK4584"],"gpt_icon":0},{"id":"2610993174","title":"Veru Inc. Charts Risky but Clearer Post-GLP-1 Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2610993174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610993174?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:20","pubTimestamp":1770855625,"startTime":"0","endTime":"0","summary":"Veru Inc (($VERU)) has held its Q1 earnings call. Read on for the main highlights of the call. Veru Inc.’s latest earnings call struck a cautiously...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/veru-inc-charts-risky-but-clearer-post-glp-1-path?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/veru-inc-charts-risky-but-clearer-post-glp-1-path?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4212","BK4590","POST","BK4584","BK4183","VERU","BK4144","BK4557","GLP","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}